The Cost-Effectiveness OF Canagliflozin (Cana) Versus Dapagliflozin (Dapa) In Patients With Type 2 Diabetes Mellitus (T2dm) With Inadequate Control On Metformin (Met) Monotherapy In The United Kingdom
Abstract
Authors
M. Schroeder P. Johansen G. Thompson M. Willis C. Neslusan